Testing lurbinectedin for small cell lung cancer that has returned
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer that has come back after one round of chemotherapy (etoposide plus platinum, possibly with immunotherapy).
- It should have been at least 30 days since your last chemotherapy before the cancer progressed.
- You need to be at least 18 years old and in generally good health (able to care for yourself, up and about more than half of waking hours).
- You must have at least one tumor that can be measured on scans.
- You cannot have had certain prior treatments like lurbinectedin, trabectedin, irinotecan, or topotecan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called LY01610 for people with small cell lung cancer that has returned after initial chemotherapy. It may offer a new treatment option for those whose cancer progressed within 6 months of their last treatment.
This trial tests whether adding lurbinectedin to paclitaxel (a standard chemo drug) helps people with small cell lung cancer that has progressed after prior treatment. You would receive either the combination or paclitaxel alone, and the study compares how well each works.
This trial studies whether adding palliative (comfort-focused) radiation to the medicine lurbinectedin can better control extensive-stage small cell lung cancer. It may help reduce problems from tumors in places like bones and organs.
This trial tests a combination of two drugs, lurbinectedin and serplulimab, as maintenance therapy after initial chemotherapy for people with extensive-stage small cell lung cancer (SCLC) that hasn't spread to the brain. The goal is to see if this approach helps keep the cancer from growing for longer.
This trial tests a combination of two drugs—lurbinectedin and durvalumab—for people with extensive-stage small cell lung cancer who have already received initial treatment. The goal is to see if this combination can help control the cancer better.
This trial tests a combination of two drugs—lurbinectedin and osimertinib—for people whose lung cancer started as EGFR-mutated non-small cell lung cancer but has changed into small cell lung cancer. The goal is to see if this combination can help control the cancer.
Hear when a new Relapsed Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.